No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer.
Open Access
- 26 November 2001
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 97 (6), 787-790
- https://doi.org/10.1002/ijc.10129
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.JNCI Journal of the National Cancer Institute, 2000
- Val659→Glu Mutation within the Transmembrane Domain of ErbB-2: Effects Measured by 2H NMR in Fluid Phospholipid BilayersBiochemistry, 2000
- The genetics of transitional cell carcinoma: progress and potential clinical applicationBJU International, 1999
- The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogeneOncogene, 1998
- HER-2/neu-targeting gene therapy-a reviewGene, 1995
- Oncogene Amplification in Urothelial Cancers With p53 Gene Mutation or MDM2 AmplificationJNCI Journal of the National Cancer Institute, 1994
- Accumulated allelic losses in the development of invasive urothelial cancerInternational Journal of Cancer, 1993
- Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185Cell, 1986
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985